Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05322577 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05322577 · ClinicalTrials.gov record · last posted 2026-07-29

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Study acronym: FORTITUDE-103
StatusTerminated
PhasePhase 1/2
SponsorAmgen
Started2022-05-17
View on ClinicalTrials.gov ↗
Why the trial stopped
Sponsor Decision
from the ClinicalTrials.gov record
The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.

Protocol amendment history 3 changes detected by DataLookout

2026-07-30
Trial terminated
2026-07-30
Trial terminated: Sponsor Decision
2026-07-30
Completion moved earlier: 2026-08-12 → 2025-11-21
Trial Details
NCT Number NCT05322577
Lead Sponsor Amgen
Conditions Gastric Cancer, Gastroesophageal Junction Cancer
Enrollment 72 participants
Start Date 2022-05-17
Primary Completion 2025-11-21 (estimated)
Study Completion 2025-11-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-29